Literature DB >> 2785168

Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion.

W Schultz1, A Studer, R Romo, E Sundström, G Jonsson, E Scarnati.   

Abstract

1. We quantitatively assessed deficits in the initiation and execution of arm movements occurring after destruction of nigrostriatal dopamine neurons by systemic administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Sigma). Three monkeys performed a reaction time task in which they reached toward a single and constant target for food reward. 2. After administration of MPTP, all three monkeys showed hypokinesia necessitating dopamine precursor or receptor agonist treatment. The partial recovery of one animal from initial akinesia after 19 days permitted discontinuation of dopaminergic drug therapy, although marked hypokinesia remained present. The two other animals displayed additional, intermittent phases of rigidity and activation tremor and needed continuous dopaminergic drug therapy for most of the postlesion period. 3. Administration of MPTP significantly prolonged EMG reaction time in prime mover muscles and arm movement reaction time by 47-225% and 18-129%, respectively, on the six sides of the three animals, compared with control measurements before the lesion. EMG and arm movement reaction time increased over consecutive trials in most sessions comprising 110-130 movements, the first 20 movements showing almost normal values. The delay time between onsets of EMG and arm movement showed unsystematic changes. These deficits in movement initiation were observed both with and without dopamine precursor therapy. They lasted during the whole testing period of several months. 4. Linear correlations between arm movement onset and EMG onset in the two prime mover muscles, the extensor digitorum communis and the biceps, showed coefficients of mostly 0.7-0.9, both before and after MPTP. These data suggest that the temporal relationship between onsets of arm movement and EMG were not substantially affected by MPTP. 5. Arm movement time was divided into two phases. The duration of movement between the resting key and the target, a small food-containing box located ahead of the animal, was denoted as reaching movement time. The following hand manipulation inside the food box was measured as box movement time. After MPTP, both measures were significantly prolonged by 10-103% and 12-251%, respectively, on the six sides of the three monkeys. These deficits in movement execution were observed both with and without dopaminergic drug therapy and during the whole testing period. 6. Task performance after MPTP treatment was studied in one monkey in the absence of dopaminergic drug therapy. EMG and arm movement reaction times recovered partially over several weeks, while the prolongations in reaching and box movement times remained unchanged.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785168     DOI: 10.1152/jn.1989.61.3.651

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  4 in total

1.  Activity in monkey substantia nigra neurons related to a simple learned movement.

Authors:  C Magariños-Ascone; W Buño; E García-Austt
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

2.  Saccadic reaction times, eye-arm coordination and spontaneous eye movements in normal and MPTP-treated monkeys.

Authors:  W Schultz; R Romo; E Scarnati; E Sundström; G Jonsson; A Studer
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

3.  Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.

Authors:  Matthew A Weber; Mackenzie M Conlon; Hannah R Stutt; Linder Wendt; Patrick Ten Eyck; Nandakumar S Narayanan
Journal:  Behav Neurosci       Date:  2022-04-07       Impact factor: 2.154

4.  Mechanisms for multiple activity modes of VTA dopamine neurons.

Authors:  Andrew Oster; Philippe Faure; Boris S Gutkin
Journal:  Front Comput Neurosci       Date:  2015-07-28       Impact factor: 2.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.